BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15571586)

  • 1. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.
    Arnott ID; Landers CJ; Nimmo EJ; Drummond HE; Smith BK; Targan SR; Satsangi J
    Am J Gastroenterol; 2004 Dec; 99(12):2376-84. PubMed ID: 15571586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
    Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
    Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
    Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
    Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.
    Papp M; Altorjay I; Norman GL; Shums Z; Palatka K; Vitalis Z; Foldi I; Lakos G; Tumpek J; Udvardy ML; Harsfalvi J; Fischer S; Lakatos L; Kovacs A; Bene L; Molnar T; Tulassay Z; Miheller P; Veres G; Papp J; ; Lakatos PL
    Inflamm Bowel Dis; 2007 Aug; 13(8):984-92. PubMed ID: 17417801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.
    Cruyssen BV; Peeters H; Hoffman IE; Laukens D; Coucke P; Marichal D; Cuvelier C; Remaut E; Veys EM; Mielants H; De Vos M; De Keyser F
    Clin Exp Immunol; 2005 May; 140(2):354-9. PubMed ID: 15807862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Mannan-binding lectin serum levels are associated with complicated Crohn's disease and reactivity to oligomannan (ASCA).
    Schoepfer AM; Flogerzi B; Seibold-Schmid B; Schaffer T; Kun JF; Pittet V; Mueller S; Seibold F
    Am J Gastroenterol; 2009 Oct; 104(10):2508-16. PubMed ID: 19532127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease--an IG-IBD study.
    Annese V; Lombardi G; Perri F; D'Incà R; Ardizzone S; Riegler G; Giaccari S; Vecchi M; Castiglione F; Gionchetti P; Cocchiara E; Vigneri S; Latiano A; Palmieri O; Andriulli A
    Am J Gastroenterol; 2005 Jan; 100(1):84-92. PubMed ID: 15654786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease.
    Smith BR; Arnott ID; Drummond HE; Nimmo ER; Satsangi J
    Inflamm Bowel Dis; 2004 Sep; 10(5):521-8. PubMed ID: 15472511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn' s disease population.
    Linskens RK; Mallant-Hent RC; Murillo LS; von Blomberg BM; Alizadeh BZ; Peña AS
    Dig Liver Dis; 2004 Jan; 36(1):29-34. PubMed ID: 14971813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn's disease in Tunisian population.
    Marrakchi R; Bougatef K; Moussa A; Ouerhani S; Khodjet-el-Khil H; Messai Y; Mestiri O; Najar T; Benammar-Elgaaeid A
    Inflamm Res; 2009 Apr; 58(4):218-23. PubMed ID: 19184350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives.
    Devlin SM; Yang H; Ippoliti A; Taylor KD; Landers CJ; Su X; Abreu MT; Papadakis KA; Vasiliauskas EA; Melmed GY; Fleshner PR; Mei L; Rotter JI; Targan SR
    Gastroenterology; 2007 Feb; 132(2):576-86. PubMed ID: 17258734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared with adults with Crohn's disease.
    Weiss B; Shamir R; Bujanover Y; Waterman M; Hartman C; Fradkin A; Berkowitz D; Weintraub I; Eliakim R; Karban A
    J Pediatr; 2004 Aug; 145(2):208-12. PubMed ID: 15289769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.
    Mow WS; Vasiliauskas EA; Lin YC; Fleshner PR; Papadakis KA; Taylor KD; Landers CJ; Abreu-Martin MT; Rotter JI; Yang H; Targan SR
    Gastroenterology; 2004 Feb; 126(2):414-24. PubMed ID: 14762777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFalpha genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type.
    Castro-Santos P; Mozo L; Gutiérrez C; Suárez A
    Clin Immunol; 2006 Dec; 121(3):305-13. PubMed ID: 16952484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population.
    O'Donnell S; O'Sullivan M; O'Morain CA; Ryan BM
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1464-9. PubMed ID: 24047859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course.
    Kim BC; Park S; Han J; Kim JH; Kim TI; Kim WH
    Dig Liver Dis; 2007 Jul; 39(7):610-6. PubMed ID: 17531556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.
    Walker LJ; Aldhous MC; Drummond HE; Smith BR; Nimmo ER; Arnott ID; Satsangi J
    Clin Exp Immunol; 2004 Mar; 135(3):490-6. PubMed ID: 15008984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
    Mokrowiecka A; Gasiorowska A; Małecka-Panas E
    Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis.
    Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis.
    Seiderer J; Schnitzler F; Brand S; Staudinger T; Pfennig S; Herrmann K; Hofbauer K; Dambacher J; Tillack C; Sackmann M; Göke B; Lohse P; Ochsenkühn T
    Scand J Gastroenterol; 2006 Dec; 41(12):1421-32. PubMed ID: 17101573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.